Zobrazeno 1 - 10
of 10
pro vyhledávání: '"Anne M. S. Belonje"'
Autor:
Wiek H. van Gilst, Lennaert Kleijn, Tiny Jaarsma, Hans L. Hillege, Peter van der Meer, Dirk J. van Veldhuisen, Rudolf A. de Boer, Anne M. S. Belonje, Adriaan A. Voors, Joseph Kim, Sudip Ghosh
Publikováno v:
Heart, 98(16), 1237-1241. BMJ Publishing Group
Heart, 98(16), 1237-1241. BMJ PUBLISHING GROUP
Kleijn, L, Belonje, A M S, Voors, A A, Jaarsma, T, Ghosh, S, Kim, J, van Gilst, W H & van Veldhuisen, D J 2012, ' Inflammation and anaemia in a broad spectrum of patients with heart failure. ', Heart, vol. 98, no. 16, pp. 1237-1241 . https://doi.org/10.1136/heartjnl-2012-301954
Heart, 98(16), 1237-1241. BMJ PUBLISHING GROUP
Kleijn, L, Belonje, A M S, Voors, A A, Jaarsma, T, Ghosh, S, Kim, J, van Gilst, W H & van Veldhuisen, D J 2012, ' Inflammation and anaemia in a broad spectrum of patients with heart failure. ', Heart, vol. 98, no. 16, pp. 1237-1241 . https://doi.org/10.1136/heartjnl-2012-301954
Aims: Anaemia in heart failure (HF) is associated with a poor prognosis. Although inflammation is assumed to be an important cause of anaemia, the association between anaemia and inflammatory markers in patients with HF has not been well established.
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::27e91a90684938ebee739abaf7107e95
https://doi.org/10.1136/heartjnl-2012-301954
https://doi.org/10.1136/heartjnl-2012-301954
Autor:
B. Daan Westenbrink, P. Ponikowski, Kenneth Dickstein, Stephan von Haehling, Adriaan A. Voors, Anne M. S. Belonje, Stefan D. Anker, Dirk J. van Veldhuisen
Publikováno v:
American Heart Journal, 157(1), 91-96. MOSBY-ELSEVIER
Background In patients with chronic heart failure, erythropoietin (Epo) levels are increased and related to a poor prognosis. Furthermore, Epo levels in these patients show a weak correlation with hemoglobin levels.Methods This is a retrospective ana
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::5d184f2d297f4547c94dc240d53f557a
https://doi.org/10.1016/j.ahj.2008.08.020
https://doi.org/10.1016/j.ahj.2008.08.020
Autor:
Regien G. Schoemaker, B. Daan Westenbrink, Hisko Oeseburg, Adriaan A. Voors, Lennaert Kleijn, Wiek H. van Gilst, Rudolf A. de Boer, Dirk J. van Veldhuisen, Anne M. S. Belonje, Pim van der Harst
Publikováno v:
Cardiovascular Drugs and Therapy, 22(4), 265-274. SPRINGER
Purpose We aimed to evaluate whether ischemia is required for erythropoietin (EPO) induced stimulation of endothelial progenitor cells (EPCs) and their related effects on endothelial and cardiac function. Methods Bone marrow of rats was replaced by t
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::ce3832a95cf395766b428cda4c7287fc
https://doi.org/10.1007/s10557-008-6094-y
https://doi.org/10.1007/s10557-008-6094-y
Publikováno v:
Congestive Heart Failure. 13:289-292
In patients with chronic heart failure (CHF), anemia is common and is associated with adverse outcome. Correction of anemia by erythropoiesis-stimulating proteins would thus seem attractive. Endogenous erythropoietin (Epo) levels are increased in CHF
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::99f37567250ffd7910e68d3829e6caf2
https://doi.org/10.1111/j.1527-5299.2007.06662.x
https://doi.org/10.1111/j.1527-5299.2007.06662.x
Autor:
Maurizio Ferrario, Sunil V. Rao, Ken Toba, Dong-Ju Choi, Ilka Ott, Fabrice Prunier, Andrew Ludman, Hans L. Hillege, Marieke L. Fokkema, Anne M. S. Belonje, Stuart D. Katz, Peter van der Meer, Adriaan A. Voors, Dirk J. van Veldhuisen, Erik Lipsic
Publikováno v:
American Heart Journal, 168(3), 354-362.e2. MOSBY-ELSEVIER
Background Erythropoiesis-stimulating agents (ESAs) have been investigated in small studies in patients with ST-elevation myocardial infarction (STEMI) undergoing primary percutaneous coronary intervention (PCI). Erythropoiesis-stimulating agents did
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::3b66f80325f315edbd717d75c31c6013
https://research.rug.nl/en/publications/1cfd5c30-647a-4760-9380-5ff9f6661165
https://research.rug.nl/en/publications/1cfd5c30-647a-4760-9380-5ff9f6661165
Autor:
Arnoud W J van 't Hof, Wiek H. van Gilst, José P.S. Henriques, Hans O. Peels, J. Wouter Jukema, Dirk J. van Veldhuisen, Sandra K. Achterhof, Peter van der Meer, Lennaert Kleijn, Adriaan A. Voors, Jurriën M. ten Berg, Hans L. Hillege, Marieke L. Fokkema, Jeroen Vos, Anne M. S. Belonje
Publikováno v:
Cardiovascular Drugs and Therapy, 27(5). Kluwer Academic Publishers
Cardiovascular Drugs and Therapy, 27(5), 433-439
fokkema, M L, Kleijn, L, van der Meer, P, Belonje, A M S, Achterhof, S K, Hillege, H L, van't Hof, A W J, Jukema, J W, Peels, H O, Henriques, J P, ten Berg, J M, Vos, J, van Gilst, W H, van Veldhuisen, D J & Voors, A A 2013, ' Long term effects of epoetin alfa in patients with ST-elevation myocardial infarction. ', Cardiovascular Drugs and Therapy, vol. 27, no. 5 . https://doi.org/10.1007/s10557-013-6470-0
Cardiovascular Drugs and Therapy, 27(5), 433-439. SPRINGER
Cardiovascular drugs and therapy / sponsored by the International Society of Cardiovascular Pharmacotherapy, 27(5), 433-439. Kluwer Academic Publishers
Cardiovascular Drugs and Therapy, 27(5), 433-439
fokkema, M L, Kleijn, L, van der Meer, P, Belonje, A M S, Achterhof, S K, Hillege, H L, van't Hof, A W J, Jukema, J W, Peels, H O, Henriques, J P, ten Berg, J M, Vos, J, van Gilst, W H, van Veldhuisen, D J & Voors, A A 2013, ' Long term effects of epoetin alfa in patients with ST-elevation myocardial infarction. ', Cardiovascular Drugs and Therapy, vol. 27, no. 5 . https://doi.org/10.1007/s10557-013-6470-0
Cardiovascular Drugs and Therapy, 27(5), 433-439. SPRINGER
Cardiovascular drugs and therapy / sponsored by the International Society of Cardiovascular Pharmacotherapy, 27(5), 433-439. Kluwer Academic Publishers
Purpose: The HEBE III trial showed that epoetin alfa administration in patients with a first ST-elevation myocardial infarction (STEMI) did not improve left ventricular function at 6 weeks after primary percutaneous coronary intervention (PCI). The l
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::23b7524ae6b14bae6d72f951f0d44bc9
https://hdl.handle.net/1887/102223
https://hdl.handle.net/1887/102223
Autor:
Rudolf A. de Boer, Wiek H. van Gilst, Mariusz K. Szymanski, Anne M. S. Belonje, Dirk J. van Veldhuisen, Eveline van der Veer, Herman H W Silljé, Licette C. Y. Liu, Tiny Jaarsma, Adriaan A. Voors
Publikováno v:
Liu, L C Y, Voors, A A, van Veldhuisen, D J, van de Veer, E, Belonje, A M S, Szymanski, M K, Sillje, H H W, van Gilst, W H & de Jaarsma, R A 2011, ' Vitamin D status and outcomes in heart failure patients. ', European Journal of Heart Failure, vol. 13, no. 6, pp. 619-625 . https://doi.org/10.1093/eurjhf/hfr032
European Journal of Heart Failure, 13(6), 619-625. Wiley
European Journal of Heart Failure, 13(6), 619-625. Oxford University Press
European Journal of Heart Failure, 13(6), 619-625. Wiley
European Journal of Heart Failure, 13(6), 619-625. Oxford University Press
Aims Vitamin D status has been implicated in the pathophysiology of heart failure (HF). The aims of this study were to determine whether a low vitamin D status is associated with prognosis in HF and whether activation of the renin-angiotensin system
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::005dda1173031882bc761b2b05ede02b
https://research.vu.nl/en/publications/47bd7be8-2d4f-4ec9-9483-47a525fb9b24
https://research.vu.nl/en/publications/47bd7be8-2d4f-4ec9-9483-47a525fb9b24
Autor:
Peter van der Meer, Dirk J. van Veldhuisen, Anne M. S. Belonje, Tiny Jaarsma, Adriaan A. Voors, Wiek H. van Gilst
Publikováno v:
Circulation, 122(10), E450-E450. LIPPINCOTT WILLIAMS & WILKINS
We thank Dr Incalzi and coauthors for their thorough reading of our article.1 They raise an important issue on chronic obstructive pulmonary disease (COPD)–related arterial hypoxemia and its influence on erythropoietin production. We agree that bes
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::b16aacaeb5390619941125502ee275ba
https://research.rug.nl/en/publications/9fbab381-2eee-4d24-8d62-a5c186b16536
https://research.rug.nl/en/publications/9fbab381-2eee-4d24-8d62-a5c186b16536
Autor:
Peter van der Meer, Adriaan A. Voors, Dirk J. van Veldhuisen, Anne M. S. Belonje, Tiny Jaarsma, Wiek H. van Gilst
Publikováno v:
Circulation, 121(2), 245-251. LIPPINCOTT WILLIAMS & WILKINS
Background— Endogenous erythropoietin is increased in patients with heart failure (HF). Previous small-scale data suggest that these erythropoietin levels are related to prognosis. This study aims to analyze the clinical and prognostic value of ery
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::c083c154f857b3fb3778e10f90d0eec4
https://research.rug.nl/en/publications/f9886110-34b7-44ec-bc9b-7105344424df
https://research.rug.nl/en/publications/f9886110-34b7-44ec-bc9b-7105344424df
Publikováno v:
Cardiovascular Drugs and Therapy. 22:1-2
For over two decades now, the recombinant form of erythropoietin (RhEPO) is used for the treatment of anemia in end-stage renal disease patients. Initial studies indicated an improvement in quality of life [1]. However, neutral/ negative data from tw
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_________::601d559772a2f0ea0789347afb0eb1cf
https://doi.org/10.1007/s10557-008-6079-x
https://doi.org/10.1007/s10557-008-6079-x